A. Bidault

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2018 .

Multiple peritoneal calcifying fibrous tumors revealed by ischemic colitis.

T. Lazure, G. Pelletier, C. Buffet, 2007, Annals of diagnostic pathology.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

F. Carbonnel, J. Blanc, J. Taieb, 2014, Annals of Surgical Oncology.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.